Expression of STEAP-1 and p40 in Prostatic Carcinoma and Its Mimickers

NCT05428319 | Unknown

• 1 other identifier: Soh-Med-22-06-14
• Study Type: observational
• Target: 70
• Locations: 1 country
• Sites: 1

Brief Summary

Prostatic carcinoma is the second most common cancer in men with high incidence of morbidity and mortality. It is a common health problem. Most cases occur at the age of 50 years, reaching its peak at 60-70 years of age. Diagnosis of prostatic carcinoma is still a problematic issue as accurate diagnosis can be very challenging due to the presence of either a small focus of cancer or the presence of many benign mimickers of malignancy. Six transmembrane epithelial antigen of the prostate 1 (STEAP-1) is primarily localized at the cell membrane, mostly at cell-cell junctions, but it may also be found dispersed in the cytoplasm. In prostate, the expression of STEAP-1 is higher in neoplastic tissues compared to its restricted expression in normal prostatic samples. The antibody designated as p40 recognizes exclusively ΔNp63 and not TAp63. In prostate tissues, it has been shown that p40, the ΔNp63 isoform of p63, stains prostatic basal cells as reliable as p63 in most cases. Furthermore, aberrant staining of tumor cells was seen more rarely with p40 than with p63. In this study, the investigators hope to solve some problematic issues in diagnosis of prostatic carcinoma and reach the better way to distinguish prostatic carcinoma from mimicking lesions by using both STEAP-1 and p 40. Also, the way to detect cancer at early stage of development and its progression which is extremely important as it allows establishing the most effective treatment and predicting patient's outcome.

Conditions

Prostatic Carcinoma

Outcome Measures

Primary Outcomes (1)

• Diagnosis of Prostatic Carcinoma

  Immunohistochemical Expression of STEAP-1 and p40 in Prostatic carcinoma and mimickers

  One or two days after staining sections with the markers

Eligibility Criteria

• Sex: male
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Formalin-fixed and paraffin embedded prostatic tissue blocks from 70 patients

You may qualify if:

• Trans-rectal ultrasound guided biopsy (TRUS) procedure, transurethral resection prostatectomy (TURP) and radical prostatectomy.
• Prostatic adenocarcinoma and prostatic lesions that mimic prostatic adenocarcinoma

You may not qualify if:

• Patients with recurrence of the primary tumor.
• Patients with a history of preoperative chemotherapy and/or radiotherapy.
• Insufficient or tiny tissue biopsies

Sponsors & Collaborators

• Sohag University: lead

Study Sites (1)

Aliaa Bakr Ahmed

Sohag, 201, Egypt

Location

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Study Officials

• Aliaa Bakr

  Faculty of medicine, Sohag University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Aliaa B Ahmed

CONTACT

01062157907; aliaa.bek0@gmail.com

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant lecturer

Study Record Dates

• First Submitted: June 16, 2022
• First Posted: June 23, 2022
• Study Start: December 1, 2022
• Primary Completion: August 1, 2024
• Study Completion: December 1, 2024
• Last Updated: September 8, 2022

Record last verified: 2022-09

Locations

EG (1)